Wed, Aug 27, 2014, 6:18 AM EDT - U.S. Markets open in 3 hrs 12 mins

Recent

% | $
Quotes you view appear here for quick access.

Genworth Financial, Inc. Message Board

hounddoggiect 33 posts  |  Last Activity: Aug 17, 2014 3:19 PM Member since: Oct 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I am thinking the short rib barbecue may start on Monday after all these positive articles going on over the weekend...

    Sentiment: Strong Buy

  • Reply to

    Summary

    by ntrldan Aug 17, 2014 3:00 PM
    hounddoggiect hounddoggiect Aug 17, 2014 3:17 PM Flag

    They will be needing medication... I believe that they will developed diabetes based on the intake of carbohydrates over the next 90 days....Future customers....

    Sentiment: Strong Buy

  • Reply to

    VP of Sanofi in France comment's on Afrezza

    by hounddoggiect Aug 17, 2014 12:12 PM
    hounddoggiect hounddoggiect Aug 17, 2014 12:40 PM Flag

    Should I mention anything else ? don't be overcome by fear from WS Short institutions dominating the share price for they own interest as they begin to cover behind close doors.... buy and hold against their will don't set stop losses or they will sweep them like #$%$ in the streets. If you have any commons sense what so ever you will HOLD and add at these historical levels.

    Sentiment: Strong Buy

  • hounddoggiect by hounddoggiect Aug 17, 2014 12:34 PM Flag

    Buy, HOLD and be long and prosper..........(Ignore the day to day drama)....

    Sentiment: Strong Buy

  • According to Sanofi VP Pierre Chancel, “Afrezza is a further addition to our growing portfolio of integrated diabetes solutions. It is uniquely positioned to provide patients with another insulin therapy option to manage their diabetes but does not require multiple daily injections.” Given that Sanofi's long acting insulin, Lantus, is facing patent expiration in February 2015, Afrezza would be a godsend not only for patients with diabetes but also for Sanofi, as our multidisciplinary research shows that Afrezza should take complete dominance in the $29 billion U.S. insulin market, growing at the rate of 12.4 percent annually and expected to reach $45 billion by 2020.

    Facing Lantus' upcoming patent expiration, Sanofi has already partnered with Regeneron (NASDAQ: REGN) to commercialize Regeneron's revolutionary anti-lipid drug alirocumab – a powerful drug that posted excellent phase 3 data in its unparalleled ability to reduce LDL-cholesterol with similar safety yet much better efficacy than the Illustrious Blockbuster drug, Lipitor, that recognized more than $12 billion peak revenue for Pfizer. Now with Afrezza on board, Sanofi will not only be replacing Lantus’ upcoming loss in revenues due to its patent's cliff, but the French drugmaker will catalyze its next phase of earnings growth

    Sentiment: Strong Buy

  • Reply to

    WOW- and 150 mill goes to

    by bubaamadeus Aug 17, 2014 11:46 AM
    hounddoggiect hounddoggiect Aug 17, 2014 12:00 PM Flag

    It will be paid in cash by 2019

    Sentiment: Strong Buy

  • http://ipacrs.org/assets/uploads/outputs/11-MannKind.pdf

    Sentiment: Strong Buy

  • hounddoggiect hounddoggiect Aug 17, 2014 8:53 AM Flag

    I honestly believe that we will be in the $30's maybe $40's by end of 2015, look at the recent article posted and statement of Sanofi's President in Isreal alone. Wallstreet is protecting their 70 Mil institutions short sales... this is ending this week..IMO

    Sentiment: Strong Buy

  • Reply to

    THIS SELL OFF

    by stonex9758 Aug 16, 2014 1:00 PM
    hounddoggiect hounddoggiect Aug 17, 2014 8:52 AM Flag

    Sorry wrong board.... MNKD I meant

  • Reply to

    THIS SELL OFF

    by stonex9758 Aug 16, 2014 1:00 PM
    hounddoggiect hounddoggiect Aug 17, 2014 8:51 AM Flag

    I honestly believe that we will be in the $30's maybe $40's by end of 2015, look at the recent article posted and statement of Sanofi's President in Isreal alone. Wallstreet is protecting their 70 Mil institutions short sales... this is ending this week..IMO

    Sentiment: Strong Buy

  • Reply to

    Diabetes medication looks promising - Part 2

    by hounddoggiect Aug 17, 2014 8:46 AM
    hounddoggiect hounddoggiect Aug 17, 2014 8:48 AM Flag

    Do the Math..

    "one popular fast-acting pen insulin costs about $270 per month, without insurance coverage, for a person who needs 30 units a day"

    Now can you see what an opportunity you have to buy under $7.00 ?......

    Sentiment: Strong Buy

  • The time you inhale Afrezza to the time it actually peaks in the blood is 15 to 20 minutes, which is faster than injected insulin taken before a meal. The body also clears Afrezza more quickly than insulin injected at mealtimes, being pretty much gone in two or three hours. With Afrezza, there is also less weight gain than with injected insulin, which is thought to be due to the shorter time Afrezza remains in the body.

    This may be a great thing for people with diabetes who want to avoid shots, which is probably up to 15 percent of people on insulin. But some experts are taking a wait-and-see approach until they can show there is no risk to the lung tissue and the mouth and esophagus.

    The expectation is Afrezza should be priced comparably to current fast-acting injected insulins delivered in pen form. Although prices for the fast-acting insulin pens vary, one popular fast-acting pen insulin costs about $270 per month, without insurance coverage, for a person who needs 30 units a day.

    Before you get your hopes up and schedule an appointment with your doctor to discuss this new form of insulin, please understand that it is not available at your pharmacy yet. But expect it to be coming soon.

    Dr. Terry Gaff is a physician in northeast Indiana

    Sentiment: Strong Buy

  • Diabetes medication looks promising

    I can remember many patients that refused to consider insulin because of the shots, even when their diabetes was nowhere near being under control on diet, exercise and pills. But a few years ago, there was an insulin product that seemed like the answer to their prayers because it could be inhaled instead of injected.

    It was called Exubera and was approved by the Food and Drug Administration in 2006 but withdrawn from the market by its maker, Pfizer, in 2007, mainly because of low sales and inconvenience. Health care providers had to spend a half hour or so just to explain how to use the Exubera inhaler.

    This year, however, the FDA has approved a drug called Afrezza, which is a rapid-acting inhaled insulin to be taken before meals or within 20 minutes of starting a meal.

    The Afrezza inhaler is relatively small, easy to use, and it takes less than a minute to train a patient how to use the insulin.

    It is not a substitute for long-acting insulin and must be used in combination with long-acting insulin in patients with type 1 diabetes. It is not recommended for the treatment of diabetic ketoacidosis or in patients who smoke or who have chronic lung disease, like emphysema or asthma.

    The most common bad side effects with Afrezza in early testing were hypoglycemia (low blood sugar), cough and throat pain or irritation. Afrezza will have a specific warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease (COPD).

    The FDA is also requiring further studies on Afrezza after the drug is released for use. They will be evaluating its use, safety and effectiveness in pediatric patients. They will also be watching for the potential risk for lung cancer with Afrezza, along with assessment of heart disease risk and long-term effect on lung function.

    Sentiment: Strong Buy

  • Reply to

    Recognize these words?

    by cedafuntennis Aug 16, 2014 3:55 AM
    hounddoggiect hounddoggiect Aug 17, 2014 8:28 AM Flag

    Amen Brother... A lot of people here do have the opportunity of making a pretty big fortune by having patience and a little intelligence. Long 10,000 shares.

    Sentiment: Strong Buy

  • hounddoggiect hounddoggiect Aug 16, 2014 4:46 PM Flag

    I sell short ribs........

    Sentiment: Strong Buy

  • MannKind Corporation: Is MannKind a Victim of Manipulation and Corruption on Wall Street

    Disclosure: We are long on MNKD and we do not have any financial relationships with any of the company we cover.

    The Story.MannKind Corporation (NASDAQ: MNKD) recently inked the commercial partnership agreement with Sanofi this past Monday August 11, 2014. Contrary to what shareholders hoped to be the bulls run that should have caused an epic short squeeze, the bears stood firm in The Street. Prior to the market open on Monday, share price initially traded north by more than 30 percent, only to give up nearly all gains, and closed slightly north of 4.9 percent. Shares have been hampered by declining trend and close the week, down by 16 percent at $6.86 on Friday, August 14, 2014.

    Long-term shareholders and traders were distraught with the shares price action on MannKind. Some shareholders publicly raise the question whether MannKind's trading has to do with The Street's Senior Columnist, Adam Feuerstein, and his along with others potential manipulation on MannKind. The Street's Founder, Jim C. Cramer, is also the host of the "Mad Money" show on CNBC. Interestingly the viewers on CNBC Mad Money have dropped significantly over the years.

    More Insights. Shareholders are fed up with Adam Feuerstein as the Citizens for Responsibility and Ethic in Washington (or CREW) stated in their letter to the Security Exchange Commission on July 29, "in March 2014, Mr. Feuerstein published an article predicting a 60-percent chance the Food and Drug Administration (FDA) would reject the company’s new drug, Afrezza. By the end of the day, Mannkind shares were trading at a 10-month low.

    Source: Citizens For Ethics

    Sentiment: Strong Buy

  • "There is even an article announcing that the drug will be soon available in Israel."

    Sentiment: Strong Buy

  • Reply to

    Uptownbull222

    by jerginsa Aug 15, 2014 8:27 PM
    hounddoggiect hounddoggiect Aug 16, 2014 8:21 AM Flag

    It will happen, relax....

    Sentiment: Strong Buy

  • Reply to

    Understanding the $175mm line of credit

    by kingedxxxxx Aug 15, 2014 12:18 PM
    hounddoggiect hounddoggiect Aug 15, 2014 5:19 PM Flag

    Exactly, he has one agenda only... bash

    Sentiment: Strong Buy

  • hounddoggiect by hounddoggiect Aug 15, 2014 5:04 PM Flag

    up from here.....

    Sentiment: Strong Buy

GNW
14.03+0.05(+0.36%)Aug 26 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.